Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

80.0%

4 terminated/withdrawn out of 5 trials

Success Rate

20.0%

-66.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03483922Completed

HCC Screening Using DNA Methylation Changes in ctDNA

Role: lead

NCT03499678Terminated

Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA

Role: lead

NCT03494803Withdrawn

Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC

Role: lead

NCT03734419Withdrawn

The Use of Aging Biomarkers in Saliva, Based on DNA Methylation Status in Elovl2 to Predict Biological Age

Role: lead

NCT03480659Terminated

Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC

Role: lead

All 5 trials loaded